How is the law on parallel imports of medicines affected by the European Courts ruling on 6 January 2004 that Bayer was entitled to refuse to supply its drugs to wholesalers in certain countries?
This ruling concerns competition issues (private sector practices regarding supplies) and does not alter the Court’s case law on free movement of goods or state measures regarding parallel imports. It does not, therefore, have any impact on the content of the Communication, which explains the rulings of the Court on free movement of goods.
Related Questions
- How is the law on parallel imports of medicines affected by the European Courts ruling on 6 January 2004 that Bayer was entitled to refuse to supply its drugs to wholesalers in certain countries?
- Wouldn’t this law conflict with the Supreme Court’s Hazelwood ruling?
- Who is affected by the Supreme Court ruling?
